Camptothecin schedule and timing of administration with irradiation

ONCOLOGY

Volumn 15, Issue 3 SUPPL. 5, 2001, Pages 37-41

  Rich, Twin A ^a   Kirichenko, Alexander V ^b  

^a Department of Radiation Oncology ^*  (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; RADIATION SENSITIZING AGENTS; RADIOSENSITIZING AGENT;

COLORECTAL TUMOR; DRUG ADMINISTRATION; HUMAN; REVIEW; TIME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMAN; RADIATION-SENSITIZING AGENTS; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0035292570     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Rothenberg ML: Current Status of Irinotecan (CPT-11) in the United States: The Camptothecins From Discovery to the Patient, p 272. New York, The New York Academy of Sciences, 1996.
2. Rich TA: Irradiation plus 5-fluorouracil: Cellular mechnisms of action and treatment schedules. Semin Radiat Oncol 7:267-273, 1997.
3. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994.
4. Cunningham D: Setting a new standard - Irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two phase III studies and implications for clinical practice. Semin Oncol 26(1 suppl 5):1-5, 1999.
5. Iveson TJ, Hickish T, Schmitt C, et al: Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 35(13):1796-1804, 1999.
6. Byfield JE, Calabro, Jones P, et al: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays. Int J Radiat Oncol Biol Phys 8:1923-1933, 1982.
7. Kirichenko AV, Rich TA, Newman RA, et al: Potentiation of murine MCA-4 carcinoma radioresponse by 9-amino20(S)-camptothecin. Cancer Res 57:1929-1933, 1997.
8. Kirichenko AV, Rich TA: Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 44:659-664, 1999.
9. Hall EJ: Radiology for the Radiologist, 4th ed, p 16. Philadelphia, JB Lippincott, 1994.
10. Pommier Y: DNA topoisomcrase I and II in cancer chemotherapy: Update and perspectives. Cancer Chemother Pharmacol 32:103-108, 1993.